Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors

Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors

Show other versions (1)

Mutation in the CTNNB1 gene, leading to a deregulation of the WTN/β-catenin pathway, is a common feature of desmoid tumors (DTs). Many β-catenin inhibitors have recently been tested in clinical studies; however, BC2059 (also referred as Tegavivint), a selective inhibitor of nuclear β-catenin that wo...

Full description

Bibliographic Details
Main Authors: Danielle Almeida Braggio, Fernanda Costas C. de Faria, David Koller, Feng Jin, Abeba Zewdu, Gonzalo Lopez, Kara Batte, Lucia Casadei, Meng Welliver, Stephen K. Horrigan, Ruolan Han, Jeffrey L. Larson, Anne M. Strohecker, Raphael E. Pollock
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565452/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565452/?tool=EBI

Similar Items